
Harm Reduction Group - Q3 2023 could prove to be the starting point of long sequential growth

Redeye updates its estimates following Harm Reduction Group's Q3 report. The quarter was slightly softer than expected, which we believe is due to the DAGAB distribution agreement progressing slower than expected. We are, however, positive about the coming quarters, where the agreement should bear significant fruit, and we believe this could be the starting point of long sequential growth.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Harm Reduction Group - Q3 2023 could prove to be the starting point of long sequential growth](#)